|
KMID : 0360220160570020243
|
|
Journal of the Korean Ophthalmological Society
2016 Volume.57 No. 2 p.243 ~ p.247
|
|
|
Comparison of Short-Term Clinical Outcomes between Intravitreal Ranibizumab and Aflibercept in Retinal Angiomatous Proliferation
|
|
김오제:Kim Oh-Jae
김재휘:Kim Jae-Hui/김종우:Kim Jong-Woo/이태곤:Lee Tae-Gon/조성원:Cho Sung-Won/이동원:Lee Dong-Won/한정일:Han Jung-Il/김철구:Kim Chul-Gu
|
|
|
Abstract
|
|
|
Purpose: To evaluate the 6-month outcomes of intravitreal ranibizumab and aflibercept treatment for patients with retinal angiomatous proliferation (RAP).
Methods: A retrospective review of medical records of 28 patients (31 eyes) diagnosed with RAP was performed. All patients were initially treated with 3 consecutive intravitreal ranibizumab or aflibercept injections after diagnosis. Additional treatment was performed when exudation recurred. The best-corrected visual acuity (BCVA) and central foveal thickness were measured before the first injection and 3 and 6 months after the first injection. The values measured before the treatment were compared with those after treatment.
Results: Sixteen eyes were treated with ranibizumab and 15 eyes with aflibercept. The logarithm of minimal angle of resolution (log MAR) values of BCVA before the first injection and 3 and 6 months after the first injection were 0.78 ± 0.50, 0.47 ± 0.30 and 0.59 ± 0.41 in the ranibizumab group and 0.96 ± 0.52, 0.83 ± 0.52 and 0.74 ± 0.56 in the aflibercept group, respectively. Central foveal thickness was 315.75 ± 115.44, 188.38 ± 57.33 and 218.50 ± 96.49 μm in the ranibizumab group and 249.00 ± 74.88, 143.73 ± 32.73 and 196.73 ± 94.08 μm in the aflibercept group, respectively. BCVA was significantly improved and central foveal thickness was significantly reduced at 6 months (p < 0.05) compared to measurements before the first injection in both groups. However, BCVA improvement and central foveal thickness were not significantly different between the 2 groups.
Conclusions: Both intravitreal ranibizumab and aflibercept treatments were beneficial for both normalizing macular thickness and improving visual acuity in patients with RAP. The efficacy of the 2 drugs was not noticeably different.
|
|
|
KEYWORD
|
|
|
Aflibercept, Clinical outcomes, Ranibizumab, Retinal angiomatous proliferation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|